Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Mar 3, 2021 9:55am
Novartis presented positive study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum from nurses and patients using its Kesimpta auto-injector pen for MS. (Novartis)
Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses.
Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over rival administration methods.
The kudos from a small, 130-participant study come as Novartis bids to make Kesimpta a first-treatment option. Kesimpta’s chief rival Roche’s Ocrevus, which also works by targeting CD20-expressing B-cells is an infusion treatment.
Senior Editor
Women with MS who continue their disease-modifying therapy, or DMT, throughout pregnancy have lower hospitalization costs and use, compared to those who discontinued their therapy.
That finding comes from a retrospective study conducted by Walgreens in collaboration with AllianceRx Walgreens Prime to understand how non-adherence to these women’s DMTs would impact healthcare cost and utilization over a two-year period. The researchers presented the findings on Feb. 26 at the virtual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021.
MS is a chronic condition affecting the central nervous system that affects roughly 2.3 million people worldwide, with women affected two to three times as often as men. According to the National MS Society, none of the DMTs are approved for use during pregnancy yet discontinuing DMTs may cause relapse of disease. However, for certain DMTs, studies do indicate that some patients continue thei